Adult patients with locally advanced rectal cancer who have completed conventional
long-course chemo-radiation of 54Gy with capecitabine will be randomized 1:1 to a total
neo-adjuvant therapy (TNT) protocol or to a control group. Patients in the TNT arm will
receive 4 cycles of interval chemotherapy with FOLFIRINOX (5-FU, irinotecan, oxaliplatin)
between the end of chemo-radiation and re-staging and those in the control group will undergo
standard post-radiation care during this period. All patients will be re-staged with
colonoscopy and pelvic MRI 12 weeks after the end of chemo-radiation. Those with a complete
clinical response will be placed under a watch-and-wait protocol with digital rectal
examinations every 2 months and pelvic MRI and sigmoidoscopy every 6 months. Those wih
residual tumors will undergo resection with total mesorectal excision (TME). Patients with a
"near complete response", as defined by a multidisciplinary tumor board, will be re-staged at
week 16 or 18 after chemo-radiation before undergoing surgery. Adjuvant chemotherapy will be
done following the local standard of care.
Hospital Israelita Albert Einstein
1Research sites
150Patients around the world
This study is for people with
Colorectal cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Age >= 18 y/o
Biopsy-confirmed rectal adenocarcinoma
Tumor Stage T3+ or N+ M0
Adequate liver function (total bilirubin < = 4.0)
Adequate kidney function (calculate creatinine-clearance >=30ml/m2/min)
Adequate bone marrow function (Platelet counts >=90.000, hemoglobin >=8mg/dl, neutrophile count >= 1.500/cm3)
Completed chemo-radiation with at least 54Gy and capecitabine 1650mg/m2/d